• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

    1/6/22 7:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANEB alert in real time by email

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately.

    In this position, Mr. Anderson will report directly to Rex Merchant, Anebulo's Chief Financial Officer. Mr. Anderson will be responsible for Anebulo's global investor relations and public relations programs. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders.

    Mr. Anderson will build on Anebulo's current investor relations and public relations programs to grow and diversify the Company's shareholder base as well as to enhance its communications with shareholders and other stakeholders. Scott will work closely with the management team to further develop the company's internal and external communications with a focus on strategy, branding, social media presence and investor communications.

    Mr. Anderson brings more than 20 years of public company experience to Anebulo, having served in various investor relations and corporate communications roles at such companies as Qualcomm, Qorvo (formerly RF Micro Devices), Actavis plc (formerly Watson Pharmaceuticals), and O2Micro International Limited.

    Commenting on the appointment, Dr. Daniel Schneeberger, CEO, said: "We are extremely pleased to welcome Scott to the Anebulo Team. His experience and insights make him ideally suited to support the continued development of our investor relations program and goals. Based on our plans to report topline results from our ongoing Phase 2 trial in the first half of the year, it is a great time to bolster our investor relations program and ensure best practices to drive shareholder value."

    Mr. Anderson added, "I'm delighted to be joining Anebulo at this unique and exciting time. I look forward to assisting Anebulo to communicate the Company's strategic initiatives and performance drivers to the financial community and its key stakeholders."

    Mr. Anderson earned a B.A. degree in Communication Arts & Sciences from the Annenberg School for Communication and Journalism at the University of Southern California.

    About Anebulo Pharmaceuticals, Inc.

    Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1) with good oral bioavailability and brain penetration (rat brain:plasma ratio of approximately 1.5). Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated, and may lead to weight loss, an effect that is consistent with CB1 antagonism in the central nervous system. For further information about Anebulo, please visit www.anebulo.com.

    Forward-Looking Statements

    This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as "anticipate," "expect," "intend," "may," "will," "should" and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company's product candidates, and those described in Anebulo Pharmaceutical's most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005069/en/

    Get the next $ANEB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANEB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANEB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lawler Joseph F.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:39 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shah Bimal R.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:38 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Cundy Kenneth C

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:37 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Leadership Updates

    Live Leadership Updates

    See more
    • Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

      10/6/23 4:06:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

      Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer.  Ms. Gardiner joins Anebul

      3/8/23 8:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys

      11/1/22 4:00:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Financials

    Live finance-specific insights

    See more

    $ANEB
    SEC Filings

    See more
    • Ligand Reports Third Quarter 2023 Financial Results

      Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

      11/8/23 4:01:00 PM ET
      $AMGN
      $ANEB
      $JAZZ
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ligand Reports First Quarter 2023 Financial Results

      2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

      5/4/23 4:01:00 PM ET
      $ANEB
      $LGND
      $NOVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

      Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of

      7/5/22 6:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/15/25 4:15:33 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/11/25 7:04:26 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/4/25 6:09:38 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing. FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediat

      2/14/25 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise. In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children Anebu

      12/23/24 9:15:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2024, and recent updates. First Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo announced it has been awarded the first tranche of a two-year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), under award number 1U01DA059995-01. With the support of NIDA, Anebulo aims to complete IND-enabling

      11/13/24 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      12/26/24 4:15:08 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care